Biote Corp BTMD.OQ BTMD.O is expected to show a rise in quarterly revenue when it reports results on November 12 for the period ending September 30 2024
The Irving Texas-based company is expected to report a 12.8% increase in revenue to $51.384 million from $45.56 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.
LSEG's mean analyst estimate for Biote Corp is for earnings of 9 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Biote Corp is 9.94, above its last closing price of $5.56.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2024 | 0.08 | 0.09 | -0.15 | Missed | -273.1 |
Mar. 31 2024 | 0.03 | 0.03 | -0.06 | Missed | -280 |
Dec. 31 2023 | 0.08 | 0.08 | 0.18 | Beat | 134.8 |
Sep. 30 2023 | 0.08 | 0.08 | 0.24 | Beat | 220 |
Jun. 30 2023 | 0.09 | 0.10 | -0.25 | Missed | -363.2 |
Mar. 31 2023 | 0.09 | 0.09 | -0.39 | Missed | -533.3 |
Dec. 31 2022 | 0.14 | 0.18 | Beat | 28.6 | |
Sep. 30 2022 | 0.14 | 0.14 | -1.74 | Missed | -1,388.9 |
This summary was machine generated November 9 at 00:59 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。